Catherine Wood's URGN Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 121,484 shares of UroGen Pharma Ltd. (URGN) worth $2.85 M, representing 0.02% of the portfolio. First purchased in 2017-Q4, this long-term strategic position has been held for 33 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in URGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 218,101 shares. Largest reduction occurred in Q4 2022, reducing 84,763 shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's UroGen Pharma (URGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly UroGen Pharma (URGN) Trades by Catherine Wood
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -5,236 | Reduce 4.13% | 121,484 | $23.42 |
| Q3 2025 | -39,374 | Reduce 23.71% | 126,720 | $19.95 |
| Q2 2025 | -19,696 | Reduce 10.60% | 166,094 | $13.70 |
| Q1 2025 | +45,642 | Add 32.57% | 185,790 | $11.06 |
| Q4 2024 | +18,514 | Add 15.22% | 140,148 | $10.65 |
| Q3 2024 | -30,147 | Reduce 19.86% | 121,634 | $12.70 |
| Q2 2024 | +5,452 | Add 3.73% | 151,781 | $16.78 |
| Q1 2024 | -15,196 | Reduce 9.41% | 146,329 | $15.00 |
| Q4 2023 | -53,747 | Reduce 24.97% | 161,525 | $15.00 |
| Q3 2023 | +13,354 | Add 6.61% | 215,272 | $14.01 |
| Q2 2023 | -68,828 | Reduce 25.42% | 201,918 | $10.35 |
| Q1 2023 | +73,808 | Add 37.48% | 270,746 | $9.24 |
| Q4 2022 | -84,763 | Reduce 30.09% | 196,938 | $8.87 |
| Q3 2022 | -20,423 | Reduce 6.76% | 281,701 | $8.32 |
| Q2 2022 | -31,348 | Reduce 9.40% | 302,124 | $5.32 |
| Q1 2022 | +146,979 | Add 78.81% | 333,472 | $8.71 |
| Q4 2021 | -57,672 | Reduce 23.62% | 186,493 | $9.51 |
| Q3 2021 | -72,083 | Reduce 22.79% | 244,165 | $16.82 |
| Q2 2021 | +24,378 | Add 8.35% | 316,248 | $15.27 |
| Q1 2021 | +218,101 | Add 295.65% | 291,870 | $19.48 |
| Q4 2020 | +39,557 | Add 115.62% | 73,769 | $18.02 |
| Q3 2020 | -12,996 | Reduce 27.53% | 34,212 | $19.29 |
| Q2 2020 | +30,387 | Add 180.65% | 47,208 | $26.12 |
| Q1 2020 | +796 | Add 4.97% | 16,821 | $17.83 |
| Q4 2019 | +1,790 | Add 12.57% | 16,025 | $33.39 |
| Q3 2019 | +706 | Add 5.22% | 14,235 | $23.81 |
| Q2 2019 | +4,522 | Add 50.21% | 13,529 | $35.92 |
| Q1 2019 | -2,291 | Reduce 20.28% | 9,007 | $36.97 |
| Q4 2018 | +40 | Add 0.36% | 11,298 | $43.02 |
| Q3 2018 | +1,820 | Add 19.28% | 11,258 | $47.26 |
| Q2 2018 | -4,064 | Reduce 30.10% | 9,438 | $49.80 |
| Q1 2018 | +4,218 | Add 45.43% | 13,502 | $49.70 |
| Q4 2017 | +9,285 | Add 0.00% | 9,284 | $37.16 |
Catherine Wood's UroGen Pharma Investment FAQs
Catherine Wood first purchased UroGen Pharma Ltd. (URGN) in Q4 2017, acquiring 9,284 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held UroGen Pharma Ltd. (URGN) for 33 quarters since Q4 2017.
Catherine Wood's largest addition to UroGen Pharma Ltd. (URGN) was in Q1 2021, adding 291,870 shares worth $5.69 M.
According to the latest 13F filing for Q4 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 121,484 shares of UroGen Pharma Ltd. (URGN), valued at approximately $2.85 M.
As of the Q4 2025 filing, UroGen Pharma Ltd. (URGN) represents approximately 0.02% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.
Catherine Wood's peak holding in UroGen Pharma Ltd. (URGN) was 333,472 shares, as reported at the end of Q1 2022.